Is psychosexual therapy a reliable alternative to bupropion extended-release to promote the sexual function in infertile women? An RCT


Background: Various treatment methods are used to deal with sexual problems.

Objective: This study was applied to answer the question of whether psychosexual therapy (PST) can be a reliable alternative to bupropion extended-release (BUP ER) to promote sexual function in infertile women.

Materials and Methods: In this randomized clinical trial, 105 infertile women with sexual dysfunction were randomly allocated to three groups: PST, BUP ER, and a control group. The PST group participated in a total of eight 2-hr group sessions. In BUP ER group, 150 mg/day Bupropion ER was administered for eight weeks. The control group did not receive any interventions. The female sexual function index (FSFI) and a clinical interview were used to assess their sexual dysfunction.

Results: The mean pre-to-post treatment scores of FSFI and its subscales increased significantly in PST and BUP ER groups (except in the subscale of sexual pain) (p = 0.0001, p = 0.0001). The changes in the subjects were not significant in the control group. After adjusting for the baseline values, the results remained significant for the mean FSFI (p = 0.0001), and its subscales between the groups. Compared to the control group, a significant increase was observed in the mean FSFI (p = 0.0001, p = 0.002) and its subscales in the PST group and in the BUP ER group (except in the subscale of sexual pain). Comparison of two intervention methods showed that PST had the better effect on the sexual function improving (p = 0.0001) and its subscales (exempting the subscale of orgasm) than BUP ER.

Conclusion: PST can be considered not only a reliable alternative to pharmacotherapy; it also produces better results in terms of improving sexual function in infertile women.

Key words: Infertility, Sexual activities, Drug therapy, Psychotherapy, Bupropion.

[1] Safarinejad MR. Female sexual dysfunction in a population-based study in Iran: prevalence and associated risk factors. Int J Impot Res 2006; 18: 382–395.

[2] European Humanist Federation. What are sexual and reproductive health and rights? Available at: /What-are-sexual-and-reproductive-health-and-rig hts-EHF-briefing-F.pdf.

[3] Furukawa AP, Patton PE, Amato P, Li H, Leclair CM. Dyspareunia and sexual dysfunction in women seeking fertility treatment. Fertil Steril 2012; 98: 1544–1548.

[4] Basirat Z, Pasha H, Esmailzadeh S, Faramarzi M. Evaluation of the female sexual dysfunction in a sample of Iranian infertile women. British Journal of Medicine & Medical Research 2014, 4: 5825–5838.

[5] Krakowsky Y, Grober ED. A practical guide to female sexual dysfunction: An evidence-based review for physicians in Canada. Can Urol Assoc J 2018; 12: 211–216.

[6] Millheiser LS, Helmer AE, Quintero RB, Westphal LM, Milki AA, Lathi RB. Is infertility a risk factor for female sexual dysfunction? A case-control study. Fertil Steril 2010; 94: 2022–2025.

[7] Althof SE, Leiblum SR, Chevret-Measson M, Hartmann U, Levine SB, McCabe M, et al. Psychological and interpersonal dimensions of sexual function and dysfunction. J Sex Med 2005; 2: 793–800.

[8] Fruhauf S, Gerger H, Schmidt HM, Munder T, Barth J. Efficacy of psychological interventions for sexual dysfunction: a systematic review and meta-analysis. Arch Sex Behav 2013; 42: 915–933.

[9] Franken RE. Human Motivation.6th Ed. Australia, Thomson Wadsworth; 2007.

[10] Clayton AH, Warnock JK, Kornstein SG, Pinkerton R, Sheldon-Keller A, McGarvey EL. A placebo-controlled trial of bupropion SR as an antidote for selective serotonin reuptake inhibitor-induced sexual dysfunction. J Clin Psychiatry 2004; 65: 62–67.

[11] Brown AD, Blagg J, Reynolds DS. Designing drugs for the treatment of female sexual dysfunction. Drug Discov Today 2007, 12: 757–766.

[12] Safarinejad MR, Hosseini SY, Asgari MA, Dadkhah F, Taghva A. A randomized, double-blind, placebo-controlled study of the efficacy and safety of bupropion for treating hypoactive sexual desire disorder in ovulating women. BJU Int 2010; 106: 832–839.

[13] Segraves RT, Croft H, Kavoussi R, Ascher JA, Batey SR, Foster VJ, et al. Bupropion sustained release (SR) for the treatment of hypoactive sexual desire disorder (HSDD) in nondepressed women. J Sex Marital Ther 2001; 27: 303–316.

[14] Chehri A, Shahgoli N, Saberi M. [Sampling and sample size calculation in medical research]. 2nd Ed. Tehran, Pejvac Elm Arya; 2007: 76–77. (In Persian)

[15] Mohammadkhani P, Tamannaiy-Far Sh, Jahanie- Tabedh O. [Mindfulness based cognitive therapy for depression]. 1st Ed. Tehran, Faradid Publication; 2005. (In Persian)

[16] Crowe M, Ridley J. Therapy with couples: A Behavioral-Systems Approach to Marital and Sexual Problems. Oxford, Blackwell Science; 2000.

[17] Bahadoran K, Pournaseh M. A path to tranquility 5, Mindfulness and Medication. Tehran: Mehr kavian; 2009. 1–140.

[18] Croft H, Settle E Jr, Houser T, Batey SR, Donahue RM, Ascher JA. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin Ther 1999, 21: 643–658.

[19] Ginzburg R, Wong Y, Fader JS. Effect of bupropion on sexual dysfunction. Ann Pharmacother 2005; 39: 2096–2099.

[20] Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, et al. The female sexual function index (FSFI): A multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 2000; 26: 191–208.

[21] Noorbala AA, Ramazanzadeh F, Malekafzali H, Abedinia N, Forooshani AR, Shariat M, et al. Effects of a psychological intervention on depression in infertile couples. Int J Gynaecol Obstet 2008; 101: 248–252.

[22] Kornstein SG, Clayton AH. Women’s Mental Health, an Issue of Psychiatric Clinics of North America [eBook]. June 2010. Available from: Elsevier.

[23] Behboodi Moghadam Z, Rezaei E, Khaleghi Yalegonbadi F, Montazeri A, Arzaqi SM, Tavakol Z, et al. The effect of sexual health education program on women sexual function in Iran. J Res Health Sci 2015; 15: 124–128.

[24] Faubion SS, Rullo JE. Sexual dysfunction in women: A practical approach. Am Fam Physician 2015; 92: 281–288.

[25] Fugl-Meyer KS, Bohm-Starke N, Damsted Petersen C, Fugl-Meyer A, Parish S, Giraldi A. Standard operating procedures for female genital sexual pain. J Sex Med 2013; 10: 83–93.

[26] Mohammadi s, Ozvkouban M, Goodarzi F. [Effectiveness of Sexual Skills in Increasing the Women’s Marital Satisfaction]. J Couns Res 2014; 13: 139–164. (in Persian)

[27] Eshghi R, Bahrami F, Fatehizadeh M, Keshavarz A. [Studying the Effectiveness of Couples Sexual Cognitive – Behavioral Therapy on Improvement of Women’s Hypoactive Sexual Desire Disorder in Isfahan]. J Counsel Res 2015; 14: 111–130. (In Persian)

[28] Thase ME, Clayton AH, Haight BR, Thompson AH, Modell JG, Johnston JA. A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability. J Clin Psychopharmacol 2006; 26: 482–488.

[29] Koshino Y, Bahk WM, Sakai H, Kobayashi T. The efficacy and safety of bupropion sustainedrelease formulation for the treatment of major depressive disorder: a multi-center, randomized, double-blind, placebo-controlled study in Asian patients. Neuropsychiatric Dis Treat 2013; 9: 1273–1280.

[30] Pereira VM, Arias-Carrión O, Machado S, Nardi AE, Silva AK. Sex therapy for female sexual dysfunction. Intl Arch Med 2013; 6: 37–45.

[31] Faramarzi M, Pasha H, Esmailzadeh S, Kheirkhah F, Heidary S, Afshar Z. The effect of the cognitive behavioral therapy and pharmacotherapy on infertility stress: a randomized controlled trial. Int J Fertil Steril 2013; 7: 199–206.

[32] Shams Mofaraheh Z, Shahsiah M, Mohebi S, Tabaraee Y. The effect of marital counseling on sexual satisfaction of couples in Shiraz city. Health System Research 2010; 6: 417–424. (in Persian)

[33] Avasthi A, Grover S, Sathyanarayana Rao TS. Clinical practice guidelines for management of sexual dysfunction. Indian J Psychiatry 2017; 59 (suppl.): s91–s115.